Episode
Quantum Drug Discovery and the Path to Advantage with Sabrina Maniscalco
- Published
- Jun 15, 2026
- Duration seconds
- 2709
- Processing state
not_requested- Canonical source
- https://newquantumera.transistor.fm/97
Actions
POST https://stenobird.com/v1/public/podcasts/the-new-quantum-era-innovation-in-quantum-computing-science-and-technology-5609388/episodes/quantum-drug-discovery-and-the-path-to-advantage-with-sabrina-maniscalco/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-new-quantum-era-innovation-in-quantum-computing-science-and-technology-5609388/quantum-drug-discovery-and-the-path-to-advantage-with-sabrina-maniscalco.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
What does it actually take to run a quantum-classical workflow on a real cancer drug — not hydrogen, not a toy molecule, but a photosensitizer already in Phase II clinical trials? Sabrina Maniscalco, CEO and co-founder of Algorithmiq, joins Sebastian to unpack the science behind the company's Wellcome Leap Q4Bio win, its €18M raise, and its move from Helsinki to Milan. Along the way: error mitigation, tensor networks, sampling tradeoffs across hardware platforms, and an honest look at where quantum advantage in chemistry might actually land.